• 1

    O'Callaghan FJ: Tuberous sclerosis: epidemiological research is needed to complement new findings in genetics. BMJ 318: 1019, 1999.

  • 2

    Jozwiak J, Jozwiak S, Wlodarski P: Possible mechanisms of disease development in tuberous sclerosis. Lancet Oncol 9: 73, 2008.

    • Crossref
    • PubMed
    • Web of Science
    • Search Google Scholar
    • Export Citation
  • 3

    Crino PB, Nathanson KL, Petri Henske E: The tuberous sclerosis complex. N Engl J Med 355: 1345, 2006.

  • 4

    Jozwiak J, Wlodarski P: Hamartin and tuberin modulate gene transcription via beta-catenin. J Neurooncol 79: 229, 2006.

  • 5

    Al-Saleem T, Wessner LL, Scheithauer BW, et al: Malignant tumors of the kidney, brain, and soft tissues in children and young adults with the tuberous sclerosis complex. Cancer 83: 2208, 1998.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6

    Krishnan ML, Commowick O, Jeste SS, et al: Diffusion features of white matter in tuberous sclerosis with tractography. Pediatr Neurol 42: 101, 2010.

    • Crossref
    • PubMed
    • Web of Science
    • Search Google Scholar
    • Export Citation
  • 7

    Aldrich SL, Chien-Hui H, Groves L, et al: Acral lesions in tuberous sclerosis complex: insights into pathogenesis. J Am Acad Dermatol 63: 244, 2009.

    • Crossref
    • Web of Science
    • Search Google Scholar
    • Export Citation
  • 8

    Ma D, Darling T, Moss J, et al: Histologic variants of periungual fibromas in tuberous sclerosis complex. J Am Acad Dermatol 64: 442, 2011.

    • Crossref
    • PubMed
    • Web of Science
    • Search Google Scholar
    • Export Citation
  • 9

    Józwiak J, Sontowska I, Ploski R: Frequency of TSC1 and TSC2 mutations in American, British, Polish and Taiwanese populations. Mol Med Rep 8: 909, 2013.

    • Crossref
    • PubMed
    • Web of Science
    • Search Google Scholar
    • Export Citation
  • 10

    Hake S: Cutaneous manifestations of tuberous sclerosis. Ochsner J 10: 200, 2010.

  • 11

    Lee N, Woodrum CL, Nobil AM, et al: Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models. BMC Pharmacol 9: 8, 2009.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12

    Sampson JR: Therapeutic targeting of mTOR in tuberous sclerosis. Biochem Soc Trans 37: 259, 2009.

    • Crossref
    • PubMed
    • Web of Science
    • Search Google Scholar
    • Export Citation

Pedal Cutaneous Manifestations of Tuberous Sclerosis

Rachel E. Johnson Department of Podiatric Medicine, Kent State University College of Podiatric Medicine, Independence, OH.

Search for other papers by Rachel E. Johnson in
Current site
Google Scholar
PubMed
Close
 DPM, RN
and
Kimberly Avramaut University Hospitals Richmond Medical Center, Richmond Heights, OH.

Search for other papers by Kimberly Avramaut in
Current site
Google Scholar
PubMed
Close
 DPM
Restricted access

This case report concerns a patient with a painful soft-tissue mass on his fourth toe. He was evaluated for this soft-tissue mass and was diagnosed as having tuberous sclerosis. The podiatric physician should be able to evaluate a patient with a lower-extremity complaint and relate whether this complaint may correlate with a systemic disorder. This case report will make the podiatric physician more aware of tuberous sclerosis and the manifestations of the disorder.

Corresponding author: Rachel E. Johnson, DPM, RN, Department of Podiatric Medicine, Kent State University College of Podiatric Medicine, 6000 Rockside Woods Blvd, Independence, OH 44131. (E-mail: rjohn112@kent.edu)